Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 2/20 | 0.41 |
| ▸ | FGF1 | P05230 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | MGAM | O43451 | 4/20 | 0.36 |
| ▸ | SI | P14410 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | PYGB | P11216 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LRAT | O95237 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12019429 | 1.00 | LGALS8 (0.41) | LGALS8FGF1CA1CA2CA9 | |
| SCHEMBL26878917 | 1.00 | LGALS8 (0.41) | LGALS8FGF1CA1CA2CA9 | |
| SCHEMBL14748251 | 1.00 | LGALS8 (0.41) | LGALS8FGF1CA1CA2CA9 | |
| SCHEMBL26878966 | 1.00 | LGALS8 (0.41) | LGALS8FGF1CA1CA2CA9 | |
| SCHEMBL12917667 | 1.00 | LGALS8 (0.41) | LGALS8FGF1CA1CA2CA9 | |
| SCHEMBL12589717 | 1.00 | LGALS8 (0.41) | LGALS8FGF1CA1CA2CA9 | |
| SCHEMBL24980481 | 1.00 | LGALS8 (0.41) | LGALS8FGF1CA1CA2CA9 | |
| SCHEMBL19718576 | 0.89 | MEN1 (0.46) | FGF1LMNAKDM4EALOX15MEN1 | |
| SCHEMBL11941427 | 0.89 | MEN1 (0.46) | FGF1LMNAKDM4EALOX15MEN1 | |
| SCHEMBL13488460 | 0.89 | MEN1 (0.46) | FGF1LMNAKDM4EALOX15MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11155647-B2 | Water-soluble polysaccharide derivatives, process for their preparation, and their uses | JOINTHERAPEUTICS S.R.L. (IT) | 2021-10-26 | — | — | US | disclosed |
| US-20210187170-A1 | ABSORBABLE IRON-BASED IMPLANTABLE DEVICE | BIOTYX MEDICAL (SHENZHEN) CO., LTD. (CN) | 2021-06-24 | — | — | US | disclosed |
| US-20200354480-A1 | WATER SOLUBLE NITRIC OXIDE-RELEASING POLYGLUCOSAMINES AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2020-11-12 | — | — | US | disclosed |
| US-20200297755-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING JOINT INFLAMMATION | JOINTHERAPEUTICS S.R.L. (IT) | 2020-09-24 | — | — | US | disclosed |
| EP-1881009-B1 | CHITOSAN DERIVATIVE AND METHOD FOR PRODUCING SAME | UNIV NAGOYA NAT UNIV CORP (JP) | 2015-01-07 | — | — | EP | disclosed |
| US-7772382-B2 | Chitosan derivative and method of producing same | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20090062519-A1 | Chitosan Derivative and Method of Producing Same | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1881009-A1 | CHITOSAN DERIVATIVE AND METHOD FOR PRODUCING SAME | National University Corporation Nagoya University (JP) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200297755-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING JOINT INFLAMMATION | TLR6, TLR3, TLR1 | LGALS8 380/4885FGF1 207/4885CA1 1473/4885 |
| US-11155647-B2 | Water-soluble polysaccharide derivatives, process for their preparation, and their uses | CD44, ALG1, CSGALNACT1 | LGALS8 250/4885FGF1 1222/4885CA1 1436/4885 |
| US-20210187170-A1 | ABSORBABLE IRON-BASED IMPLANTABLE DEVICE | FTH1, SLC40A1, SI | LGALS8 257/4885FGF1 1391/4885CA1 71/4885 |
| US-20200354480-A1 | WATER SOLUBLE NITRIC OXIDE-RELEASING POLYGLUCOSAMINES AND USES THEREOF | NOS3, NOS2, NOS1 | LGALS8 80/4885FGF1 2014/4885CA1 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.